DISORDERS OF THROMBOPOIETIN SYNTHESIS IN VIRAL HEPATITIS AND ITS COMPLICATIONS, SOME CHANGES IN THE HEMOSTASIS SYSTEM, AND THEIR DIAGNOSTICS
Keywords:
thrombopoietin, hemostatic system, plateletsAbstract
Thrombopoietin is a protein also known as megakaryocyte growth factor. Thrombopoietin is a glycoprotein hormone produced primarily in the liver and to a lesser extent by the kidneys and smooth muscle, and regulates the production of platelets by the bone marrow. It stimulates the production and differentiation of megakaryocytes, bone marrow cells. Megakaryocytopoiesis is the process of cell development that leads to the production of platelets. In the liver, thrombopoietin is produced by parenchymal cells and sinusoidal endothelial cells, and in the kidneys by cells of the proximal convoluted tubule. In addition, thrombopoietin is produced by smooth muscle cells and bone marrow stromal cells. When its synthesis is impaired, thrombocytopenia is observed, which is one of the main factors in the development of the hemostatic system. This article discusses these problems and provides some diagnostic criteria.
References
1. Agarwal S., Joyner KAJr., Swaim MW Ascites fl uid as a possible origin for hyper fi brinolysis in advanced liver disease // Am. J. Gastroenterol. 2000. Vol. 95. P. 3218–3224.
2. Albornoz L. et al. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels // J. Hepatol. 1999. Vol. 30. P. 451–455.
3. Ben-Ari Z., Osman E., Hutton RA, Burroughs AK Disseminated intravascular coagulation in liver cirrhosis: fact or fiction ? // Am. J. Gastroenterol. 1999. Vol. 94. P. 2977–2982.
4. Bhattacharya M. et al. Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India // Am. J. Clin. Pathol. 2004. Vol. 121. P. 844–847.
5. Bismuth H. et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience // Ann. Surg. 1995. Vol. 222. P. 109–119.
6. Bosch J. et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial // Gastroenterology. 2004.Vol. 127. P. 1123–1130.
7. Burroughs AK et al. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study // J. Hepatol. 2002. Vol. 37. P. 463–470.
8. B. Kadyrov, F. Khamrabayeva. Helicobacter pylori and peptic ulcer disease, as well as views on eradication therapy//New Day in Medicine. – 2022. – V 1, No. 39. – P. 195–200.
9. Khamraboeva Feruza Ibragimovna, Kodirov Bekhruz Saidovich. Vegetativnye rasstroystva i ee rol v razvitii yazvennoy bolezny zludka i dvenadtsatiperstnoy kishki//problemy biologii i meditsiny-- 2021 yil 3 (136). b – 239-243.
10. Al-Qahtani AA, Al-Anazi MR, Nazir N, Abdo AA, Sanai FM, Al-Hamoudi WK, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, et al. The correlation between hepatitis B virus Precore/core mutations and the progression of severe liver disease. Front Cell Infect Microbiol. 2018 Oct 22;8:355.
11. Al-Sadeq DW, Taleb SA, Zaied RE, Fahad SM, Smatti MK, Rizeq BR, Al Thani AA, Yassine HM, Nasrallah GK. Hepatitis B virus molecular epidemiology, host virus interaction, co-infection, and laboratory diagnosis in the MENA Region: an Update. Pathogens. 2019 May 11;8(2):63.
12. Ambachew H, Zheng M, Pappoe F, Shen J, Xu Y. Genotyping and sero-virological characterization of hepatitis B virus (HBV) in blood donors, Southern Ethiopia. PLoS One. 2018 Feb 20;13(2):e0193177.
13. Ganczak M, Topczewska K, Budnik-Szymoniuk M, Korzeń M. Seroprevalence of anti-HBc, risk factors of occupationally acquired HBV infection and HBV vaccination among hospital staff in Poland: a multicenter study. BMC Public Health. 2019 Dec;19(1):298.
14. Gilead Sciences. Prescribing information: VEMLIDY® (tenofovir alafenamide) [Internet]. Foster City (USA): Gilead Sciences; 2015 [cited 2020 Sep]. Available from https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf
